Pfizer (PFE) Restructuring Costs (2009 - 2026)

Pfizer (PFE) has 18 years of Restructuring Costs data on file, last reported at $49.0 million in Q1 2026.

• Restructuring Costs for Q1 2026 came in at $49.0 million, down 92.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $978.0 million (down 53.54% YoY), and the FY2025 annual result was $1.6 billion, down 21.99% from the prior year.
• Restructuring Costs slipped to $49.0 million in Q1 2026 per PFE's latest filing, from $766.0 million in the prior quarter.
• Over five years, Restructuring Costs peaked at $1.6 billion in Q4 2023 and troughed at -$74.0 million in Q2 2025.
• A 5-year average of $365.4 million and a median of $189.0 million in 2022 frame the typical range for Restructuring Costs.
• The sharpest annual moves came in 2022 and 2023: Restructuring Costs surged 19000.0% in 2022, then sank 122.92% in 2023.
• A 5-year view of Restructuring Costs shows it stood at $177.0 million in 2022, then surged by 798.87% to $1.6 billion in 2023, then sank by 80.33% to $313.0 million in 2024, then soared by 144.73% to $766.0 million in 2025, then slumped by 93.6% to $49.0 million in 2026.
• Business Quant data shows PFE's Restructuring Costs at $49.0 million in Q1 2026, $766.0 million in Q4 2025, and $237.0 million in Q3 2025.